Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor ...
Roche received expanded approval from the Food and Drug Administration for a test to diagnose breast cancer. The pharmaceutical company said Monday that the FDA approved the PATHWAY HER2 (4B5) test ...
Roche Holding AG’s shares just posted their best month since 1997, lifted by optimism over an experimental breast cancer pill ...
LONDON, Dec 10 (Reuters) - Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer ...
Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, ...
Designed for use in doctor’s offices, clinics and emergency rooms, the PCR diagnostic aims to deliver results in fewer than ...
More than nine in 10 patients treated with Roche’s next-generation Alzheimer’s disease antibody trontinemab tested negative for amyloid plaques in a mid-stage study, marking a return to the ...
Roche’s data on Wednesday come from the Phase III lidERA Breast Cancer study, which assessed the adjuvant use of giredestrant ...
GlobalData on MSN
Roche gains CE Mark for bacterial vaginosis/candida vaginitis assay
The assay is currently available in nations that recognise the CE Mark.
The results of the lidERA trial in patients with HR-positive, HER2-negative early breast cancer – previewed last month and ...
The stock gained 19% last month after Roche said its giredestrant medicine helped women with a form of early breast cancer. Additionally, news of two late-stage trials showed that a multiple sclerosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback